HomePink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo
Email Preferences
Free Trial
Email Preferences
Free Trial
Spotlight
  • Rx-to-OTC Switch
  • Self-Care
  • AI
  • Interviews

Health
  • Deals
  • Earnings
  • New Products
  • Marketing & Advertising
  • Retail
  • Regulation
  • Compliance
  • Recalls
  • Legislation
Beauty
  • Deals
  • Earnings
  • New Products
  • Marketing & Advertising
  • Retail
  • Regulation
  • Compliance
  • Recalls
  • Legislation
Wellness
  • Deals
  • Earnings
  • New Products
  • Marketing & Advertising
  • Retail
  • Regulation
  • Compliance
  • Recalls
  • Legislation
Podcasts

Conference Coverage

Partner Insights

HBW Insight Perspectives

Exploring key commercial, policy and market trends ahead.

View

Pink Sheet

Scrip

Medtech Insight

HBW Insight

Generics Bulletin

In Vivo
HBW Insight logo
  1. Home
  2. >>HBW Insight
  3. >>Health
  4. >>Policy & Regulation

Policy & Regulation

RegulationComplianceRecallsLegislationLegal
  • Nancy Tests Infogram PDF

    Nancy Tests Infogram PDF

    Jun 29 2026 
    • By Mary Jo Laffler

    Description goes here.

  • Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

    Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

    Oct 17 2025

    Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

  • Asking For More: Supplement MPL Authority For FDA, Agency Results For Congress, Industry

    Asking For More: Supplement MPL Authority For FDA, Agency Results For Congress, Industry

    Sep 29 2025

    Following Energy and Commerce Health Subcommittee hearing about FDA’s human food and tobacco programs on 10 September, gap between what the trade groups, committee leadership and the FDA each want more of doesn’t appear to be shrinking.

  • HI-Health (Free-1): Why Children with ADHD Hate Bedtime: Solutions to ADHD Sleep Problems

    HI-Health (Free-1): Why Children with ADHD Hate Bedtime: Solutions to ADHD Sleep Problems

    Jun 14 2025 
    • By Nabil

    Children with ADHD often struggle with bedtime due to restless minds, difficulty winding down, and heightened sensitivity to nighttime distractions. This article explores the reasons behind these sleep challenges and offers practical solutions.


  • Beauty Brands Not On TikTok Shop ‘Really Missing Out’ – KO-Pack

    Beauty Brands Not On TikTok Shop ‘Really Missing Out’ – KO-Pack

    Sep 25 2024 
    • By Eileen Francis

    At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”

  • Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

    Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

    Sep 10 2024 
    • By Malcolm Spicer

    Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

  • ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

    ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

    Aug 25 2024 
    • By Malcolm Spicer

    Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.

  • ‘Inside Regulatory Affairs’ With Kenvue's Kevin Whelan

    ‘Inside Regulatory Affairs’ With Kenvue's Kevin Whelan

    Aug 23 2024

    This HBW Insight series profiles regulatory affairs specialists working in or supporting the consumer health and beauty product industries. In this installment, we speak to Kenvue's Kevin Whelan.


  • Current, Former US FDA Advisory Committee Members' Reform Idea: Allow Conflicted Experts

    Current, Former US FDA Advisory Committee Members' Reform Idea: Allow Conflicted Experts

    Aug 22 2024 
    • By Sue Sutter

    Conflicted experts should be allowed to participate as nonvoting members and panels should take a benefit-risk vote on product-specific applications, the majority of respondents said in a survey conducted by 3D Communications.

  • Evidence Challenging Safety Of Maternal Use Of Acetaminophen Amounts To ‘Speculation’ – Court

    Evidence Challenging Safety Of Maternal Use Of Acetaminophen Amounts To ‘Speculation’ – Court

    Aug 21 2024 
    • By Malcolm Spicer

    Height of plaintiff attorney’s argument to present evidence which would prompt speculation by a jury was request to parse research by Kenvue’s lead expert, who coordinated the International Consensus Statement on ADHD by the World Federation of ADHD, where he’s president.

  • California Legislation To Age-Restrict Sales Of Weight Loss Supplements, OTCs On Ice For 2024

    California Legislation To Age-Restrict Sales Of Weight Loss Supplements, OTCs On Ice For 2024

    Aug 16 2024 
    • By Malcolm Spicer

    California Senate Appropriations Committee suspends consideration of bill for current session after it and Judiciary Committee voted to recommend passing the bill earlier in session. Legislative sessions continue in Massachusetts and New Jersey with bills for similar restrictions.

  • Check Contract Manufacturers' GMP Compliance, US FDA Warns Eye Drop Firm, Lip Balm Provider

    Check Contract Manufacturers' GMP Compliance, US FDA Warns Eye Drop Firm, Lip Balm Provider

    Aug 15 2024 
    • By Malcolm Spicer

    Request to recall eye drops should be fulfilled promptly and businesses providing lip balms as promotional products must verify contract manufacturers are compliant, recent FDA warnings states. Additional letters went to Jordanian firm about testing alcohol for methane and to a Chinese firm advised that compliance with China’s quality control standards isn’t sufficient.


  • Marketing Dietary Supplements To GLP-1 Patients On Brand For Supergut Line, Up Now For iHerb

    Marketing Dietary Supplements To GLP-1 Patients On Brand For Supergut Line, Up Now For iHerb

    Aug 14 2024 
    • By Malcolm Spicer

    Supergut brand owner Uplifting Results Labs makes Gut Healthy GLP-1 Booster prebiotic fiber mix along with its snack bars and meal-replacement shakes available through GNC. IHerb launches supplements addressing side GLP-1 effects including nausea and pain, loss of muscle mass and changing blood sugar levels.

  • ‘Inside Regulatory Affairs’ With AESGP’s Christelle Anquez-Traxler and Oliver Hartmann

    ‘Inside Regulatory Affairs’ With AESGP’s Christelle Anquez-Traxler and Oliver Hartmann

    Aug 14 2024 
    • By David Ridley

    HBW Insight presents a new series profiling regulatory affairs specialists working in or supporting the consumer health and cosmetics industries. In this first installment, we speak to AESGP's Christelle Anquez-Traxler and Oliver Hartmann, senior regulatory science & strategy lead, and regulatory & legal affairs director respectively. 

  • Stay Tuned For FDA OTC Monographs Portal Update

    Stay Tuned For FDA OTC Monographs Portal Update

    Aug 14 2024 
    • By Malcolm Spicer

    With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.

  • Recordati Posts Rise In OTC Sales Despite Weak Cold & Flu Season

    Recordati Posts Rise In OTC Sales Despite Weak Cold & Flu Season

    Aug 14 2024 
    • By Tom Gallen

    OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.


  • Stay Tuned For FDA OTC Monographs Portal Update

    Stay Tuned For FDA OTC Monographs Portal Update

    Aug 13 2024 
    • By Malcolm Spicer

    With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.

  • WHO Resolution Targets OTC Antimicrobials, Industry Insists Problem Is Rx Misuse

    WHO Resolution Targets OTC Antimicrobials, Industry Insists Problem Is Rx Misuse

    Aug 13 2024 
    • By David Ridley

    A draft declaration to be presented to the UN General Assembly in September suggests that a “lack of regulation of over-the-counter use of antimicrobials” is one of the “drivers of antimicrobial resistance.” Industry, however, insists that misuse and over-prescription of antibiotics are the primary drivers of AMR, and is advocating for the text to be amended accordingly. 

  • US OTC Internal Analgesic Monograph Includes Gelcap Format, Rapid Release Indication – Court

    US OTC Internal Analgesic Monograph Includes Gelcap Format, Rapid Release Indication – Court

    Aug 10 2024 
    • By Malcolm Spicer

    Putative class-action complaint alleging false advertising for Tylenol Rapid Release gelcaps recently dismissed on J&J Consumer’s motion arguing that federal preemption prohibits requiring different or additional labeling for drugs available under FDA OTC monograph.

  • Perrigo Q2 Results Down Nearly 11% On Formula Slump Despite Women’s Health Sales Jump On Opill

    Perrigo Q2 Results Down Nearly 11% On Formula Slump Despite Women’s Health Sales Jump On Opill

    Aug 04 2024 
    • By Malcolm Spicer

    OTC private label/store brand product giant’s Q2 net sales down 10.7% to $1.1bn, but women’s health product sales jump 31.4% largely on Opill launched late in Q1. Biggest hit to results from infant formula business, down a reported 82% due to ongoing manufacturing quality-control remediation.

Norstella India logo
Twitter feedfooter-block.linkedin-linkRSS feedPodcastPodcast

About

  • About UsOpens in new window
  • Meet the Team
  • AdvertiseOpens in new window
  • Contact Us

Account

  • My Account
  • My View
  • Email Preferences
  • Start Free TrialOpens in new window

More

  • HBW Perspectives
  • Interviews
Home
Terms and ConditionsOpens in new window
Privacy PolicyOpens in new window